(AFMD) - Earnings & Price History

AFMD: - 2.05, $96.66M, -0.05 (-2.38%)

Sector: Healthcare - Industry: Biotechnology

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companys product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agree

Past AFMD reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2016-11-02-0.261.952.152.051.912.1-4.65%▲-4.88%-9.30%91.05K
2016-08-05-0.23
2016-08-04-0.233.23.093.13.093.20.32%3.23%3.56%39.44K
2016-08-03-0.233.093.163.23.043.251.27%-3.44%-2.22%146.15K
2016-08-02-0.233.162.892.922.83.21.04%8.22%9.34%228.78K
2016-05-18-0.173.093.12.962.853.12-4.52%4.39%-0.32%324.15K
2016-03-30-0.183.743.693.623.583.94-1.90%3.31%1.36%306.02K
2015-11-10-0.256.426.456.456.26.54-0.47%-0.47%182.19K
2015-08-04-0.1714.715.1214.914.0815.57-1.46%-1.34%-2.78%257.85K
2015-05-21-0.188.879.19.128.759.50.22%-2.74%-2.53%190.05K
2015-03-25-0.336.126.196.016.016.33-2.91%1.83%-1.13%127.11K
2014-11-18BMOAffimed Therap-0.332.696.26.026.496.056.517.81%▲-4.47%2.99%30.50K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades